



Universiteit  
Leiden  
The Netherlands

## **Dose optimization of oral targeted therapies in oncology**

Wit, D. de

### **Citation**

Wit, D. de. (2015, October 6). *Dose optimization of oral targeted therapies in oncology*. Retrieved from <https://hdl.handle.net/1887/35807>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/35807>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/35807> holds various files of this Leiden University dissertation.

**Author:** Wit, Djoeke de

**Title:** Dose optimization of oral targeted therapies in oncology

**Issue Date:** 2015-10-06

## Stellingen

- 1 Pazopanib plasma concentrations calculated with the use of dried blood spots are in good agreement with pazopanib concentrations measured in plasma. (*this thesis*)
- 2 Midazolam exposure as a measure of CYP3A4 activity can explain a large percentage of the variability in sunitinib drug exposure between patients. (*this thesis*)
- 3 In patients with gastrointestinal stromal tumors (GIST), the influence of major gastrectomy on drug exposure should be taken into account when starting treatment with tyrosine kinase inhibitors. (*this thesis*)
- 4 Dose reductions and everolimus induced stomatitis are strongly associated with systemic everolimus drug exposure in patients with cancer. (*this thesis*)
- 5 Dose individualization should become a standard of care and a priority in research for new small molecules in development. (*H.J. Klümper et al. Cancer Treat Rev. 2011;37(4):251-260*)
- 6 In light of the variability and the relationship between systemic exposure and clinical benefit and toxicities in mRCC, dose adjustments based on trough plasma concentrations may provide a method to optimize therapy with pazopanib by maintaining therapeutically effective blood levels, while minimizing AEs whenever possible. (*Suttle et al. Br J Cancer. 2014;111(10):1909-1916*)
- 7 As we enter an era of targeted anticancer agents with a monthly cost measured in thousands of dollars, we should view drug-drug or drug-food interactions as opportunities to lower costs. (*M. Ratain et al. J Clin Oncol. 2007;25(23):3397-3398*)
- 8 If it were not for the great variability among individuals, medicine might as well be a science, not an art. (*Sir William Osler, 1892*)
- 9 With self-discipline, all things are possible. (*Theodore Roosevelt, 1858*)
- 10 Lose your dreams and you might lose your mind. (*Ruby Tuesday, Rolling Stones*)

## Stellingen

- 1 Pazopanib plasma concentrations calculated with the use of dried blood spots are in good agreement with pazopanib concentrations measured in plasma. (*this thesis*)
- 2 Midazolam exposure as a measure of CYP3A4 activity can explain a large percentage of the variability in sunitinib drug exposure between patients. (*this thesis*)
- 3 In patients with gastrointestinal stromal tumors (GIST), the influence of major gastrectomy on drug exposure should be taken into account when starting treatment with tyrosine kinase inhibitors. (*this thesis*)
- 4 Dose reductions and everolimus induced stomatitis are strongly associated with systemic everolimus drug exposure in patients with cancer. (*this thesis*)
- 5 Dose individualization should become a standard of care and a priority in research for new small molecules in development. (*H.J. Klümper et al. Cancer Treat Rev. 2011;37(4):251-260*)
- 6 In light of the variability and the relationship between systemic exposure and clinical benefit and toxicities in mRCC, dose adjustments based on trough plasma concentrations may provide a method to optimize therapy with pazopanib by maintaining therapeutically effective blood levels, while minimizing AEs whenever possible. (*Suttle et al. Br J Cancer. 2014;111(10):1909-1916*)
- 7 As we enter an era of targeted anticancer agents with a monthly cost measured in thousands of dollars, we should view drug-drug or drug-food interactions as opportunities to lower costs. (*M. Ratain et al. J Clin Oncol. 2007;25(23):3397-3398*)
- 8 If it were not for the great variability among individuals, medicine might as well be a science, not an art. (*Sir William Osler, 1892*)
- 9 With self-discipline, all things are possible. (*Theodore Roosevelt, 1858*)
- 10 Lose your dreams and you might lose your mind. (*Ruby Tuesday, Rolling Stones*)